To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation

Launched by GENMONT BIOTECH INCORPORATION · Dec 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of probiotics on patients with diabetic kidney disease (DKD). Specifically, researchers want to see if taking a mixture of two types of probiotics—lactobacillus reuteri and lactobacillus rhamnosus—for six months can help improve blood sugar levels and kidney function in individuals with DKD. The idea is that these probiotics might help create a healthier balance of bacteria in the gut, which could lead to better overall health and slow the progression of kidney disease.

To participate in this trial, individuals need to be between 25 and 80 years old, have type 2 diabetes with stable medication for at least three months, and have certain levels of kidney function and blood sugar. However, those with type 1 diabetes, severe kidney issues, certain other health conditions, or who have taken certain medications recently may not be eligible. Participants can expect to take the probiotic powder daily and will be monitored for changes in their health over the study period. This trial is currently recruiting, so if you or someone you know is interested, it might be a great opportunity to contribute to important research in diabetic kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 25 and 80 years old
• • Suffering from type 2 diabetes and stable medication for 3 months
• • Detection of HbA1c before meals between 7% and 10%
• • Stage 1-3a diabetic nephropathies (eGFR \> 45 mL/min)
• • Microalbuminuria estimated between 30 to 300 mg/day
• Exclusion Criteria:
• • Patients with Type I Diabetes Mellius
• • Patients with inflammatory bowel disease, liver disease, liver cirrhosis, systemic lupus erythematosus, malignancy, and high blood pressure.
• • Patients with hypoglycemic coma, Diabetic ketoacidosis, hyperosmolar non-ketotic diabetic coma, or diabetes mellitus acute complications.
• • Acute infection medical history in past 3 month
• • Fasting blood glucose \>13.3 mmol/L
• • GPT\>100U/L (2.5 times than usual situation)
• • Vulnerable population (Including breeding or pregnant women, prisoner, aboriginal, disabled population)
• • Smoker or Alcoholic
• • Taking Antibiotics in past 1 month
• • Stably taking probiotics supplements in past 1 months (Yogurt or dairy products were excluded)
• • Taking immunosuppressive drug, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers in past 3 months